<s id="srsen"><object id="srsen"><blockquote id="srsen"></blockquote></object></s>

  • <tbody id="srsen"></tbody>

      <rp id="srsen"></rp>
      <dd id="srsen"></dd>
    1. <rp id="srsen"></rp>
    2. AACR Annual Meeting 2024

      March 11, 2024

      GemPharmatech will be attending the American Association for Cancer Research (AACR) Annual Meeting at the San Diego Convention Center from April 5??-10??, 2024! We look forward to having you visit us at Booth #3153, talk to our experts about your drug development plans, and learn more about our advanced mouse models and one-stop services for your preclinical research programs.


      Meet with us at AACR

      GemPharmatech has the world’s largest collection of genetically engineered mouse models. Understanding which of the 23,000 models is right for your project needs can be a daunting task—that is why we are making ourselves available all throughout the meeting to speak about your research and how we can help. 

      MEET US

      Poster Schedule:

      Our 6 meeting posters include some of our most cutting-edge research. If you are unable to attend a session, you can also book a meeting here.

      Sunday, April 7, 2024

      1:30 PM - 5:00 PM | Section 4

      Development of a novel murine model, NCG-M/hIL15, for enhanced post-HSC transplantation immunoreconstruction

      Poster Board Number:22

      1:30 PM - 5:00 PM | Section 22

      Breaking through ADCs resistance:Constructing preclinical enhertu-induced resistant model

      Poster Board Number:4

      Monday, Apr 8, 2024

      1:30 PM - 5:00 PM | Section 10

      Development and application of the NCG-hIL2 mouse model: A humanized platform for enhanced NK cell evaluation in ADCC efficacy testing

      Poster Board Number:18

      Tuesday, April 9, 2024

      9:00 AM - 12:30 PM | Section 9

      Patient-derived xenograft (PDX) models with differential HER2 expression for preclinical evaluation of HER2-targeted therapies

      Poster Board Number:14

      9:00 AM - 12:30 PM | Section 9

      BALB/c-hIL12RB1/hIL12RB2: A robust model for preclinical research in human IL-12 therapy

      Poster Board Number:13

      1:30 PM - 5:00 PM | Section 4

      NeoMab: A novel platform for fully human therapeutic antibody development

      Poster Board Number:13


      Next : BIO KOREA 2024 Previous:N/A